10x Genomics filed two patent infringement suits against Illumina in Delaware federal court, alleging the sequencing giant infringed intellectual property tied to single‑cell and spatial transcriptomics technologies. The complaints seek damages and injunctive relief as 10x broadens its legal push to protect market share in high‑value genomics niches. The litigation continues a years‑long pattern of IP disputes in next‑generation sequencing and single‑cell markets. Both companies have sizable installed bases and competing product roadmaps; the suits could shape commercial licensing, partner strategies and consolidation in multiomics tools.